IN2012CN10925A - - Google Patents
Info
- Publication number
- IN2012CN10925A IN2012CN10925A IN10925CHN2012A IN2012CN10925A IN 2012CN10925 A IN2012CN10925 A IN 2012CN10925A IN 10925CHN2012 A IN10925CHN2012 A IN 10925CHN2012A IN 2012CN10925 A IN2012CN10925 A IN 2012CN10925A
- Authority
- IN
- India
- Prior art keywords
- trifluoromethyl
- phenyl
- ethyl
- amino
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010128585 | 2010-06-04 | ||
| JP2010218299 | 2010-09-29 | ||
| PCT/JP2011/062751 WO2011152508A1 (ja) | 2010-06-04 | 2011-06-03 | 光学活性ジベンジルアミン誘導体及びその製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012CN10925A true IN2012CN10925A (es) | 2015-04-24 |
Family
ID=45066863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10925CHN2012 IN2012CN10925A (es) | 2010-06-04 | 2011-06-03 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8906895B2 (es) |
| EP (1) | EP2578574B1 (es) |
| JP (1) | JP5555320B2 (es) |
| KR (2) | KR20130111512A (es) |
| CN (2) | CN102933559B (es) |
| AU (1) | AU2011259929B2 (es) |
| BR (1) | BR112012030787A2 (es) |
| CA (1) | CA2801417C (es) |
| EA (1) | EA024241B1 (es) |
| ES (1) | ES2581557T3 (es) |
| HK (1) | HK1179959A1 (es) |
| IL (1) | IL223377A (es) |
| IN (1) | IN2012CN10925A (es) |
| MX (1) | MX338024B (es) |
| PT (1) | PT2578574E (es) |
| TW (1) | TWI492749B (es) |
| WO (1) | WO2011152508A1 (es) |
| ZA (1) | ZA201209372B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2013CN01326A (es) | 2010-07-22 | 2015-04-24 | Kowa Co | |
| EP2626351A4 (en) * | 2010-10-04 | 2014-03-12 | Kowa Co | AGENT CAPABLE OF INHIBITING THE EXPRESSION OF LIPID METABOLISM-RELATED MRNA |
| JPWO2013080999A1 (ja) * | 2011-11-29 | 2015-04-27 | 興和株式会社 | ＮＰＣ１Ｌ１及び／又はＬＩＰＧｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤 |
| TW201335109A (zh) * | 2011-12-02 | 2013-09-01 | Kowa Co | 光學活性化合物之製造方法 |
| WO2013137371A1 (ja) * | 2012-03-15 | 2013-09-19 | 興和株式会社 | 新規ピリミジン化合物及びそれらを含有する医薬 |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| EP2986599A1 (en) | 2013-04-17 | 2016-02-24 | Pfizer Inc. | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2014192903A1 (ja) | 2013-05-31 | 2014-12-04 | 興和株式会社 | ジベンジルアミン構造を有するピリミジン化合物の新規形態 |
| US10034892B2 (en) * | 2014-08-21 | 2018-07-31 | Srx Cardio, Llc | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity |
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| JPWO2016084950A1 (ja) * | 2014-11-28 | 2017-09-07 | 興和株式会社 | 医薬組成物 |
| US20170252338A1 (en) * | 2014-11-28 | 2017-09-07 | Kowa Company, Ltd. | Medicine |
| JP2019131472A (ja) * | 2016-05-31 | 2019-08-08 | 興和株式会社 | 医薬組成物 |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| BR112021013924A2 (pt) | 2019-01-18 | 2021-09-21 | Astrazeneca Ab | Inibidores de pcsk9 e métodos de uso do mesmo |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189208A (en) | 1991-07-01 | 1993-02-23 | Ethyl Corporation | Ibuprofen resolution |
| EP2149563B9 (en) * | 2007-04-13 | 2015-04-22 | Kowa Company, Ltd. | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound |
| WO2009143633A1 (en) | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
| EP2626351A4 (en) | 2010-10-04 | 2014-03-12 | Kowa Co | AGENT CAPABLE OF INHIBITING THE EXPRESSION OF LIPID METABOLISM-RELATED MRNA |
-
2011
- 2011-06-03 BR BR112012030787-8A patent/BR112012030787A2/pt not_active IP Right Cessation
- 2011-06-03 EP EP11789909.6A patent/EP2578574B1/en not_active Not-in-force
- 2011-06-03 CN CN201180027596.9A patent/CN102933559B/zh not_active Expired - Fee Related
- 2011-06-03 CA CA2801417A patent/CA2801417C/en not_active Expired - Fee Related
- 2011-06-03 AU AU2011259929A patent/AU2011259929B2/en not_active Ceased
- 2011-06-03 TW TW100119614A patent/TWI492749B/zh not_active IP Right Cessation
- 2011-06-03 CN CN201510015412.7A patent/CN104529910B/zh not_active Expired - Fee Related
- 2011-06-03 ES ES11789909.6T patent/ES2581557T3/es active Active
- 2011-06-03 PT PT117899096T patent/PT2578574E/pt unknown
- 2011-06-03 KR KR1020137000104A patent/KR20130111512A/ko active Search and Examination
- 2011-06-03 WO PCT/JP2011/062751 patent/WO2011152508A1/ja active Application Filing
- 2011-06-03 MX MX2012014149A patent/MX338024B/es active IP Right Grant
- 2011-06-03 US US13/700,849 patent/US8906895B2/en not_active Expired - Fee Related
- 2011-06-03 IN IN10925CHN2012 patent/IN2012CN10925A/en unknown
- 2011-06-03 EA EA201291447A patent/EA024241B1/ru not_active IP Right Cessation
- 2011-06-03 JP JP2012518458A patent/JP5555320B2/ja not_active Expired - Fee Related
- 2011-06-03 KR KR1020177017703A patent/KR20170078865A/ko not_active Application Discontinuation
-
2012
- 2012-12-02 IL IL223377A patent/IL223377A/en active IP Right Grant
- 2012-12-11 ZA ZA2012/09372A patent/ZA201209372B/en unknown
-
2013
- 2013-06-19 HK HK13107169.5A patent/HK1179959A1/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130111512A (ko) | 2013-10-10 |
| EA024241B1 (ru) | 2016-08-31 |
| AU2011259929A1 (en) | 2013-01-17 |
| TW201208688A (en) | 2012-03-01 |
| US8906895B2 (en) | 2014-12-09 |
| AU2011259929B2 (en) | 2014-07-31 |
| PT2578574E (pt) | 2016-06-17 |
| JPWO2011152508A1 (ja) | 2013-08-01 |
| CN102933559B (zh) | 2016-01-27 |
| ZA201209372B (en) | 2014-02-26 |
| CA2801417C (en) | 2017-07-11 |
| MX2012014149A (es) | 2013-02-27 |
| EP2578574A1 (en) | 2013-04-10 |
| ES2581557T3 (es) | 2016-09-06 |
| HK1179959A1 (zh) | 2013-10-11 |
| US20130225814A1 (en) | 2013-08-29 |
| CN104529910B (zh) | 2017-05-10 |
| IL223377A (en) | 2016-12-29 |
| JP5555320B2 (ja) | 2014-07-23 |
| CN104529910A (zh) | 2015-04-22 |
| KR20170078865A (ko) | 2017-07-07 |
| EP2578574A4 (en) | 2013-12-04 |
| EP2578574B1 (en) | 2016-04-27 |
| CA2801417A1 (en) | 2011-12-08 |
| EA201291447A1 (ru) | 2013-05-30 |
| IL223377A0 (en) | 2013-03-05 |
| TWI492749B (zh) | 2015-07-21 |
| CN102933559A (zh) | 2013-02-13 |
| MX338024B (es) | 2016-03-31 |
| WO2011152508A1 (ja) | 2011-12-08 |
| BR112012030787A2 (pt) | 2020-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012CN10925A (es) | ||
| TN2012000512A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| MA34818B1 (fr) | Anticorps anti-pcsk9 et procédés d'utilisation | |
| NZ601374A (en) | Stabilized antibody-containing liquid formulations | |
| TN2012000511A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies | |
| MA34519B1 (fr) | Anticorps anti-fap et procédés d'utilisation | |
| AR094204A1 (es) | Composiciones para el cuidado oral que contienen haluros de acido amino | |
| WO2012170607A3 (en) | Use of pcsk9 antagonists | |
| MX352823B (es) | Formulaciones de proteinas que contienen aminoacidos. | |
| AU2012283775A8 (en) | Inhibitors of Bruton's tyrosine kinase | |
| CR10290A (es) | Metodos para reducir la aglomeracion de proteina | |
| MY170656A (en) | Kinase inhibitors | |
| MA35712B1 (fr) | Anticorps anti-htra1 et leurs procédés d'utilisation | |
| EP1740183B8 (en) | Novel use for pde5 inhibitors | |
| MA34722B1 (fr) | Méthodes et compositions pour l'immunothérapie de maladies neurales | |
| UA104677C2 (ru) | Производные мочевины и их терапевтическое применение при лечении, среди прочего, заболеваний дыхательных путей | |
| NZ605873A (en) | Methods and compositions for cns delivery of arylsulfatase a | |
| MA28985B1 (fr) | Analogues de loxapine et methodes d'utilisation | |
| CL2012002948A1 (es) | Formulación acuosa estable que comprende proteina almenos 5 mg/ml de proteina cd-rap y un aminoácido cargado. | |
| EA201591379A1 (ru) | Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов | |
| CA2705357C (en) | Formulations for taci-immunoglobulin fusion proteins | |
| BR112014002173A2 (pt) | proteínas purificadas | |
| HN2008001859A (es) | Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida. | |
| ATE547110T1 (de) | Verwendung von zellen aus fettgewebe zur herstellung eines antitumoralen medikaments | |
| SG162766A1 (en) | Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors |